Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

- PMLiVE

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Recommends long-acting opioid analgesics Troxyca ER and Vantrela ER for approval

ABPI London offices

ABPI says UK role as clinical trial hub threatened by Brexit

Warns UK patients could be denied access to medical innovations as a result

Boehringer Ingelheim headquarters

Boehringer crowdsources psychiatric research team

Collaboration with BioMed X aims to identify new treatment approaches

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

- PMLiVE

Pfizer adds eczema drug with $5.2bn Anacor acquisition

Expands innovative products business with non-steroidal therapy Crisaborole

- PMLiVE

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Will collaborate on five programmes to explore the cause of genetically defined diseases

Bayer symbol

Bayer eyes liver cancer indication for Stivarga

New trial data shows improvement in overall survival in HCC patients

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links